NCT03790852终止1 期
A Phase 1/1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 121
- 试验地点
- 11
- 主要终点
- Incidence of ocular (study eye) and systemic adverse events
研究概览
简要总结
This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Wet AMD Cohort
- •Treatment naïve wet age-related macular degeneration involving the fovea.
- •A lesion area <30 mm2 (12 disc areas) of any lesion type.
- •BCVA ETDRS letter score ≤ 78 and ≥ 23 (-20/25 to -20/320 Snellen equivalent) in the study eye.
- •Decrease in vision in the study eye determined by the investigator to be primarily the result of wAMD.
- •Treatment naïve diabetic macular edema.
- •BCVA ETDRS letter score ≤ 78 and ≥ 23 (-20/25 to -20/320 Snellen equivalent) in the study eye.
- •Central subfield thickness (CST) of ≥ 300 microns on SD-OCT (Heidelberg Spectralis or equivalent).
- •Decrease in vision in the study eye determined by the investigator to be primarily the result of DME.
- •Treatment naïve retinal vein occlusion with macular edema and secondary visual impairment.
- •BCVA ETDRS letter score ≤ 78 and ≥ 23 (-20/25 to -20/320 Snellen equivalent) in the study eye.
- •Central subfield thickness (CST) of ≥ 300 microns on SD-OCT (Heidelberg Spectralis or equivalent).
- •Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) are both eligible.
- •Decrease in vision in the study eye determined by the investigator to be primarily the result of macular edema secondary to RVO.
- •General Inclusion Criteria
- •Adults ≥ 21 years.
排除标准
- •Wet AMD Cohort:
- •Choroidal neovascularization due to causes other than age-related macular degeneration in the study eye.
- •Geographic atrophy and/or subretinal fibrosis involving the fovea of the study eye.
- •Prior intravitreal anti-VEGF therapy in the study eye.
- •DME Cohort:
- •Initial diagnosis of DME of more than 6 months from screening in the study eye.
- •Hard exudates in the fovea.
- •Prior intravitreal anti-VEGF therapy or steroid injection, or steroid implant (dexamethasone or triamcinolone) in the study eye.
- •Moderate or dense vitreous hemorrhage preventing clear. visualization of the macula or optic disc in the study eye.
- •Fibrovascular proliferation or tractional retinal detachment in the posterior pole in the study eye. If traction is present outside the posterior pole, it should be considered not at risk of increasing and threatening the macula with the use of anti-VEGF injections, in the investigator's judgement.
- •RVO Cohort:
- •Initial diagnosis of RVO of more than 4 months from screening in the study eye.
- •Active retinal or iris neovascularization in the study eye.
- •Prior intravitreal anti-VEGF therapy or steroid injection, or steroid implant (dexamethasone or triamcinolone) in the study eye.
- •For all phase 1b subjects:
- •Uncontrolled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite treatment with antiglaucoma medication) in the study eye.
- •History of retinal detachment or treatment or surgery for retinal detachment in the study eye.
- •Any history of uveitis in either eye.
- •Significant media opacities, including visually significant cataract, in the study eye that might interfere with visual acuity assessments, optical coherence tomography, fundus photography, or with examination of the eye for assessment of safety.
- •Prior vitrectomy surgery in the study eye.
- •Active retinal disease other than the conditions under investigation.
- •Active ocular or periocular infection or inflammation in either eye.
研究组 & 干预措施
KSI-301 2.5 mg
Experimental
KSI-301 2.5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
干预措施: KSI-301 (Drug)
KSI-301 5 mg
Experimental
KSI-301 5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
干预措施: KSI-301 (Drug)
结局指标
主要结局
Incidence of ocular (study eye) and systemic adverse events
时间窗: Week 72
次要结局
未报告次要终点
研究者
研究点 (11)
Loading locations...
相似试验
已完成
1 期
First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)Wet Age-related Macular DegenerationNCT04747197EyePoint Pharmaceuticals, Inc.17
已完成
1 期
Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLCNon-Small Cell Lung Cancer MetastaticNCT03732274MedPacto, Inc.60
已完成
1 期
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)Head and Neck CancerNCT01911598Genentech, Inc.24
已完成
1 期
A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid TumorsAdvanced Solid TumorNCT03457532Haihe Biopharma Co., Ltd.177
终止
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaB-Cell LymphomaNon-Hodgkin LymphomaMultiple MyelomaNCT04045028Genentech, Inc.41